DelveInsight’s, “Dry Eye Disease Pipeline Insight 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Dry Eye Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Dry Eye Disease Pipeline. Dive into DelveInsight’s comprehensive report today! @ Dry Eye Disease Pipeline Outlook

 

Key Takeaways from the Dry Eye Disease Pipeline Report

• In October 2024:- Stealth BioTherapeutics Inc.- The goal of this clinical trial is to evaluate the efficacy,safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections.
• In October 2024:- Novartis Pharmaceuticals- The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren’s disease (SjD), or systemic lupus erythematosus (SLE).
• In October 2024:- Hoffmann-La Roche- The main objective of the study is evaluation of the safety and tolerability of OpRegen – Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
• In October 2024:- Amgen- The study will enroll 2 SS populations: Population 1 will include participants with moderate to high systemic disease activity; Population 2 will include participants with moderate to severe subjective symptoms. This study will include 3 periods: screening (5 weeks), treatment period (48 Weeks) and follow-up period (12 weeks). In the treatment period, participants from each of the populations will be randomized to receive subcutaneous (SC) dose of HZN-1116 or placebo.
• DelveInsight’s Dry Eye Disease pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Dry Eye Disease treatment.
• The leading Dry Eye Disease Companies such as Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine, and others.
• Promising Dry Eye Disease Therapies such as TJO-083, Licaminlimab, TL-925, Reproxalap Ophthalmic Solution (0.25%), AZR-MD-001, Cyclosporine ophthalmic solution, 0.1%, VSJ-110, and others.

 

Stay ahead with the most recent pipeline outlook for Dry Eye Disease. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Dry Eye Disease Treatment Drugs

 

Dry Eye Disease Emerging Drugs Profile

• AR-15512: Alcon

AR-15512 is an investigational eye drop currently in clinical development at Aerie as a potential treatment for the signs and symptoms of dry eye disease. The active ingredient in AR-15512 is a proprietary small-molecule selective agonist of the transient receptor potential melastatin 8 (TRPM8) cold thermoreceptor, which represents a novel therapeutic target for dry eye. The drug is currently in Phase III stage of clinical trial evaluation for the treatment of DED.

• SI-614: Seikagaku Corporation

SI-614, an ophthalmic solution being developed by Seikagaku Corporation. CT-868 is a. SI-614 is an amphiphilic polymer produced by introducing a hydrophobic group into hyaluronic acid using Seikagaku’s own proprietary technology. Ocular instillation of SI-614 in dry eye patients is thought to stabilize the tear film by utilizing the mucoadhesive and surface tension reducing properties of SI-614 and to promote corneal epithelial wound healing by binding SI-614 to the fibronectin that occurs on corneal epithelial defects to promote epithelial cell growth. Through these actions, SI-614 is expected to restore the tear film and corneal structure to their normal state and improve symptoms associated with dry eye. Currently, the drug is in the Phase III stage of development to treat Dry Eye Disease.

• HU007: Huons

HU007 is a combination of cyclosporine, an anti-inflammatory component, and trehalose, a tear film protection component, to minimize eye surface irritation such as burning sensation by lowering the concentration of cyclosporine to less than half than that of existing treatments. In addition, it is an ophthalmic agent developed to suppress the destruction of each conjunctival epithelial cells caused by drying by combining trehalose preparations and to see the combined treatment effect for dry eyes. Currently, the drug is in the Phase III stage of development to treat Dry Eye Disease.

• A197: Aramis Biosciences

A197 is a novel topical agent that targets the immunopathogenesis of dry eye disease. It has a unique mechanism of action compared to existing dry eye treatments. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

• INV 102: Invirsa, Inc.

INV 102 is an ophthalmic eye drop being developed by Invirsa, Inc. Invirsa’s lead candidate is a naturally-occurring, small molecule that modulates the activity of p53, the central protein responsible for regulating the DNA damage response. Currently, the drug is in the Phase II stage of development to treat Dry Eye Disease.

• iVIEW 1001: IVIEW Therapeutics

iVIEW 1001 is a TRPM8 agonist drug being developed by iVIEW Therapeutics, Inc. to treat dry eye diseases. IVIEW 1001 is a TRPM8 agonist, which means it stimulates the transient receptor potential melastatin 8 (TRPM8) receptors in the eyelid margin. This stimulation sends a perception of coolness, reducing ocular discomfort and potentially increasing tear secretion. Currently, the drug is in the Phase I/II stage of development to treat Dry Eye Disease.

 

Explore groundbreaking therapies and clinical trials in the Dry Eye Disease Pipeline. Access DelveInsight’s detailed report now! @ New Dry Eye Disease Drugs

 

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Dry Eye Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Unveil the future of Dry Eye Disease Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Dry Eye Disease Market Drivers and Barriers

 

Scope of the Dry Eye Disease Pipeline Report

• Coverage- Global
• Dry Eye Disease Companies- Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine, and others.
• Dry Eye Disease Therapies- TJO-083, Licaminlimab, TL-925, Reproxalap Ophthalmic Solution (0.25%), AZR-MD-001, Cyclosporine ophthalmic solution, 0.1%, VSJ-110, and others.
• Dry Eye Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dry Eye Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Dry Eye Disease Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Dry Eye Disease Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Dry Eye Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dry Eye Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. AR-15512: Alcon
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. INV 102: Invirsa, Inc.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. iVIEW 1001: IVIEW Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Dry Eye Disease Key Companies
21. Dry Eye Disease Key Products
22. Dry Eye Disease- Unmet Needs
23. Dry Eye Disease- Market Drivers and Barriers
24. Dry Eye Disease- Future Perspectives and Conclusion
25. Dry Eye Disease Analyst Views
26. Dry Eye Disease Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/